User login
Photo by James Heilman
The US Food and Drug Administration (FDA) is warning consumers not to purchase or use PNC-27, a product being promoted and sold through PNC27.com as a treatment for all cancers.
The FDA has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer.
In addition, an FDA laboratory discovered the bacteria Variovorax paradoxus in a PNC-27 solution sample for inhalation.
The FDA has not received reports of illnesses or serious adverse events related to PNC-27.
However, the agency said consumers who use a contaminated product are at risk for serious, potentially life-threatening infections.
Individuals at higher risk include vulnerable populations, such as young children, elderly people, pregnant women, and individuals with weakened immune systems.
PNC-27 may be available in various dosage forms, such as a nebulized solution, intravenous solution, vaginal suppository, or rectal suppository.
The FDA recommends that patients who have used any PNC-27 product and have concerns contact their healthcare provider as soon as possible.
The agency is also encouraging healthcare professionals and consumers to report any adverse events possibly related to the use of a PNC-27 product to the FDA’s MedWatch Adverse Event Reporting Program. 
Photo by James Heilman
The US Food and Drug Administration (FDA) is warning consumers not to purchase or use PNC-27, a product being promoted and sold through PNC27.com as a treatment for all cancers.
The FDA has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer.
In addition, an FDA laboratory discovered the bacteria Variovorax paradoxus in a PNC-27 solution sample for inhalation.
The FDA has not received reports of illnesses or serious adverse events related to PNC-27.
However, the agency said consumers who use a contaminated product are at risk for serious, potentially life-threatening infections.
Individuals at higher risk include vulnerable populations, such as young children, elderly people, pregnant women, and individuals with weakened immune systems.
PNC-27 may be available in various dosage forms, such as a nebulized solution, intravenous solution, vaginal suppository, or rectal suppository.
The FDA recommends that patients who have used any PNC-27 product and have concerns contact their healthcare provider as soon as possible.
The agency is also encouraging healthcare professionals and consumers to report any adverse events possibly related to the use of a PNC-27 product to the FDA’s MedWatch Adverse Event Reporting Program.
Photo by James Heilman
The US Food and Drug Administration (FDA) is warning consumers not to purchase or use PNC-27, a product being promoted and sold through PNC27.com as a treatment for all cancers.
The FDA has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer.
In addition, an FDA laboratory discovered the bacteria Variovorax paradoxus in a PNC-27 solution sample for inhalation.
The FDA has not received reports of illnesses or serious adverse events related to PNC-27.
However, the agency said consumers who use a contaminated product are at risk for serious, potentially life-threatening infections.
Individuals at higher risk include vulnerable populations, such as young children, elderly people, pregnant women, and individuals with weakened immune systems.
PNC-27 may be available in various dosage forms, such as a nebulized solution, intravenous solution, vaginal suppository, or rectal suppository.
The FDA recommends that patients who have used any PNC-27 product and have concerns contact their healthcare provider as soon as possible.
The agency is also encouraging healthcare professionals and consumers to report any adverse events possibly related to the use of a PNC-27 product to the FDA’s MedWatch Adverse Event Reporting Program.